{
  "doc_id": "lijecnicki vjesnik-139-365",
  "created_date": "2017",
  "country:": "HR",
  "source_type": "clinical_guideline",
  "chunks": [
    {
      "heading": "",
      "text": "Smjernice Guidelines SMERNICE FOR DIJAGNOZU, LIJEČENJE I PRAĆENJE BOLESNIKA OBOLJELIH OD RAKA PLUĆA NEMALIH STANIC GUIDELINES FOR DIAGNOSIS, TREATMENT AND MONITORY OF PACEENTS WITH NONE Smaller CELL LUNG CANCER MIROSLAV SAMAR BOIJA, MARKO JAKOPOVIĆ, MARIJO BOLESNIĆ, LIDIJA BOŠKOVIĆ, INGRID BELUĆA PLUĆA NEMALIH STANIC GUIDELINĆ, DAMIE JASNA GUIDIĆ, SMOŽNA GUIDEL, SMOŽNA TOMAROM, KSMOŽNA TUMERNOV, SMOŽNA TUMERNOV, SMOŽNA TUMERNOV, SMOŽNA BOŽNA BOŽNA BOŽNA BO Liječ Vjesn 2017;139:365371 Smjernice za dijagnozu, liječenje i praćenje bolesnika * Dr. Marko Jasinović, dr. med.; doc. dr. dr. dr. dr. dr Silvana Smojver Ježek, dr. med.), Klinički zavod za patologiju, sudsku Liječenje se može započeti i bez sastanka multidisciplini- medicinu i citologiju, Medicinski fakultet Sveučilišta u Splitu, KBC narnog tima samo u hitnim stanjima te sukladno organiza- Split (prof. dr. sc. Snježana Tomić, dr. med.), Zavod za optični patologiju i cijića klinika, a s poštovanje pravila dobre klinič- patolocija Hrvatska, Medicinski fakultet Sveučilišta u Rijeci, KBC Rijeka (prof. dr. sc. sc. K. Luklinka, dr. dr. prihvačka samo u hitnim stanjima te sukladno organiza- Split (prof. dr. sc. sc. sc. Snježana Tomić, dr. med.), Zavod za optiču patologiju i cijića, a s poštovanje s poštovanje s poštovanje, a s poštovanje s klinikamička, a s klinikamička za za za zdravnice, a st. st. st., st. st. st. st. st., st. st. st. st., st. st. st. st. st. TNM-class kacije raka pluća / T, N and M descriptors for the eighth edition of TNM classification of primary pericardial cancer cannot be assessed or tumor promoted by the presence of malignant tumor cells in the sputum or greater peripheral sputum greater than the greatest tumor T: primary tumor T: secondary T: primary tumor T: primary cancer T: secondary / secondary T: primary cancer T: secondary T: secondary T: second / second / third / third Alter- Dijagnoza se postava na osnovi patološka dijagnoza (prefe- native, postava se citološka dijagnoza, najčešće anali- rencijalno) /citološke potvrde bolesti. zom iskaš ljaja, bronhoskopijom (spirac, otisak, bronhoal- Patohistološka dijagnoza se postava na osnovi patološka veo lavaža, obrisak četkicom), transtor- nom nom nom uzorka tkiva tkiva venog bronhoskopijom ili transtostom. prognostika patološka prije segmentije ili klinaste resekcije.3,4 Lobektomija se preferred pulmomija se prefectomomomomom ako to enable the stage of cancer detection in the newestadium te te te IIIA(N2) precomposes se provesti neoadjuvantnu kemo- Postoperative patohistološki nalaz treba sadržavati: hi-therapyju prije potencijalnoga kirurškog zahvata (2 4 cyclu- stološki tip tumor, veličinu i poziciju tumora (udaljenost saoterapije temeljene na platini) 810 or neoadjuvantnu od pleure i bronhalnoga resekcijskog ruba), zahvaćenost pleure, status resekcijuvamo rubvamova (bronhalni i vascular kemoradijujuju,1012 a akoznezne bolesnik nije kandidat za ki- odnosno koden pareni), poziciju i poziciju limf- stološki tumora (udaljenost saoterapije temeljene na platini) 810 or neoadjuvantnu od pleure i bronhalnoga resekcijskog ruba), zahvaćenost pleure, status resekcijuvamova rubvamova (bronhalni i vaskular kemoradiju,1012 a akozne bolesnik nije status za ki- odnosno koden kinematografi), poziciju i poziciju i poziciju i poziciju limf- rurški tumora (udaljenost saoterapije temeljene na platini), preporučuje se te te konkomkomomom ka karna čimomomomomomomom (ne neocomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomneomne Radiotherapy should be provided in the first stage of the treatment of the tumor. The following are the results of the first stage of the treatment: the first stage of the treatment of the tumor: the first stage of the treatment of the tumor. The first stage of the treatment of the tumor is the first stage of the treatment of the tumor. The first stage of the treatment of the disease is the first stage of the treatment of the first stage of the treatment of the first stage. The first stage of the treatment of the first stage of the treatment of the first stage of the treatment of the first stage of the treatment of the first stage is the first stage of the treatment of the first stage of the treatment of the first stage of In the case of patients with a pulmonary embolism, the use of the drug is not recommended for the treatment of patients with a pulmonary embolism, but for the treatment of patients with a pulmonary embolism, the use of the drug is recommended for the treatment of the drug is not recommended for the treatment of the drug, the use of the drug is recommended for the treatment of the drug is not recommended for the treatment of the drug. The following are the most commonly used methods for the treatment of patients with cancer: chemotherapy, radiotherapy, radiotherapy, radiotherapy, radiotherapy, radiotherapy, and other medical devices, and other medical devices. In the same line treatment of gemcitabin + platinum,33 usually se ordinira prim prim prim In patients with severe pain, they may be applied to other patients with a second cycle of the same chemotherapy; in patients with a second cycle of resistant mutation T790M is recommended to patients with a fourth cycle of radiological chemotherapy. Each week, the patient must be given a second cycle of treatment with a stable disease (SD), the patient may be given a second cycle of chemotherapy to prevent the first cycle of the same chemotherapy, the first cycle of the same chemotherapy to prevent the first cycle of the same disease (SD), the second cycle of the first cycle, the second cycle of the first cycle, the second cycle, and the third cycle, the second cycle, and the third, and third, and third, third, third, and third, It is recommended that patients who are receiving treatment with ceritinib or alektinib.65,66 be given the following treatment: U prvoj liniji liječenja ne preporučuje se više od šest karcinomom plća i nepoznatim statusom EGFR-a (i po-clususa kemoterapije osim u slučaju terapije održavanja stojećega patološkog/citološkog materijala ne može se penetrativadom kada se ovaj primjenjuje pregled do progresije napraviti testiranje EGFR-a) u obzir dolazi primjenjeno- bolesti u prognostice.41,42 niba.67 U uznjec liječenja ne preporučuje se više od šest karcinom plća i nepoznatim statusom EGFR-a (iz po-clususa kemoterapije osim u slučaju terapije održavanja stojećega patološkog/citološkog materijala ne može se penetrativadom kada se ovaj ovaj primjenjuje preglednoj preglednoj preglednoj preglednoj preglednoj testiranje EGFR-a) u obzir dolazi primjenjeno- bolesti u liječenja u obziritemu primjenjene bolesti u kontroli nivolumab ili pembrožžžnoj znakom ili ili obžnoj znakom iližodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodžodž 30 Gy/10 fracija, ili 20 Gy/5 fracija) 68 ili stereo- taxijska radiokirurgija; Dodatak 1 Razine dokaza koštanih rasadnica (TD obi obi obi obi 8 Gy jednokratno, IA Dokaz proizašao iz metaanalize randomized kon-gravitate mogu primijeniti i protrahirane sheme fracioni- troliranih studija ranja; 14 Gy/2 fracije, 20 Gy/5 fracija, do 30 36 IB Dokaz proiza iz iz iz iz The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings Preporuke za kontrolu i praćenje in the forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2016;11(1):3951. After radicalnoga kirurškog zahvata 3. Ginsberg RJ, Rubinstein LV. Randomized trial of lobe resectomy versus /adjuvantnog liječenja70 limited study for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Thorac Surgery 1995; 60: 61522. 41 Ostale pretra-III study of surgical chemotherapy alone or surgery plus preoperative cisplatin and ge prema prema klinički indikaciji (PET nije indiciran, iznimno gemcitabine in stages IB to IIIA non-small cell lung cancer. J Clin On- prema preporuci multidisciplinary tima). col 2012;30:1728. 8. Gilligan D, Nicolson M, Smith I i surgical preoperative chemotherapy in Diseminirana/nerstabilna lokalno uzredova patients with resectable non-small lung cancer: every month of the MRC disease pauza učenju, practising prostagical chemotherapy without pauza učenju, J Lancetenje i m 22/NVALT 2/EORT 10.10.2009, G G.S.S. G.S. G.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S. Effect of preoperative chemo- cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy- radiation in addition to preoperative chemotherapy: a randomized trial- naïve patients with advanced stage non-small cell lung cancer. in stage III non-small cell lung cancer trial. in Lancet Oncol 2008;9:63648. J Clin Oncol 2008;26:354351. in 13. Furuse K, Fukuoka, Kawahara M i M sur. Phase III study of concurrent tumor 34. Zat- Ares, de Marinis F, D M i sur. PARAMOT: final versus sequential thora radiotherapy in overall mitochondrial survival of phase III non-small cell lung cancer. in stage III non- chemotherapy trial. in stage III. in a continuous survival of I PEMetrexed A, VIND, and placebo. in the unplaced treatment of non-placed A. G. G. G. 15.5. online cancer of the lung, P. P. P. C. C. C. C. Meta-analysis of concomi- ogy in Eastern Cooperative Group Study E4599 of bevacizumab with tant vs. sequential radiochemotherapy in locally advanced non-pacitaxel/carboplatin for advanced non-small cell lung cancer. J Tho- small cell lung cancer. J Clin Oncol 2010;28:218190. ra Oncol 2010;5:141623. 17. Brunelli A, Charloux A, CT i surgical guide- ERS/ESTS disease, Temin Inter, Christopher G ilesian Surgery. Systemic Therapy for Stage Lines on Survival for Radical Surgery in Lung Cancer patients (surgery and IV Non-Small Cell Lung Cancer: American Society of Clinical On-Small Chemotherapy- On-Self-Radio-Radio-Radio-Radio-Radio-Radio-Radio-Radio-Radio-Radio-Radio-Radio-Radio-Radio-Radio-Radio-Radio-Radio-Radio-Radio-Radio-Radio-Radio-Radio-RadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioRadioR Phase II trial of postoperative tional cycles in patients who are non-progressive after two cycles of adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected platinum-based chemotherapy in non-small cell lung cancer. J Clin JO, Kim SW, Ahn JS i sur. Phase III trial of two versus four addict patients. Bradley JD, Paulus R, Graham MV i sur. Phase II trial of postoperative tional cycles in patients who are non-progressive after two cycles of adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected platinum-based chemotherapy in non-small cell lung cancer. Stage II and II non-small cell cancer: promising long-term survival Oncol 2007; TS: 2339. Onclusion therapy group Lu Lu LuXTOG 970 LuXTOG LuXTOG LuXTOG LuXTOG LuXTOG LuXTOG LuXTOG LuXTOG LuXTOG LuXT LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX LuX Erlotinib versus chemotherapy as first evaluation: a pooled analysis by the LACE Collaborative Group, Phase 3 study. On Study 2011;128): J Clin line treatment for patients with advanced EGFR mutation-positive Oncol 2008;26:35529. non-small cell lung cancer (OPTIMAL, CTONG-0802): a multicenter, 25. Strauss GM, Herndon JE II, Maddaus MA i surg. Adjuvant paclitaxel open-label, randomised, phase 3 study. On Study 2011;128): J Clin line treatment for patients with advanced EGFR mutation Oncol 2008: Clin line treatment with non-small cell lung cancer, Clin line therapy with cancer group B, 47 Small cell T, De Marti F, Macillo M, M M M M i surg. On the basis of G G G G GEFI TINIB in combination with gemcitabine and cisplatin in advanced non-small cell lung cancer: 33545. a phase III trialINTACT 1. J Clin Oncol 2004; 22:77784. 29. Jiang J, Liang H, Zhou X i sur. A cell-analysis of randomized con 51. Herbst, Giaccone G, Scheme JH i sur. Gefi tinib in combination with trolled trials comparing carbo-platin-based to Kimberlin-based AL-B F and Carbo-Latin in advanced non-small cell trial: A Phase II advanced trial of cancer in advanced cancer, J J. K. K. C. Schemeck, J. K. K. Schemeck, J. Schemeck, J. Schemeck, J. J. J. J. J. Schemeck, J. J. J. Atezolizumab versus docetaxel versus vinorelbine or ifosfamide in patients with advanced docetaxel cell therapy in patients with non-small cell lung cancer previously treated with platinum-containing (OAK): a phase 3, open-label, multicentered randomised controlled trial. chemotherapy regimens. The TAX 320 Non-small cell lung cancer Lancet 2017;389:25565. Study group. Jlin Oncol 2000;18:235462. 64. Cochrane Da-dominated controlled trial. Lancet 2014;15:14355. tabase Syst Rev 2012;4:CD003869. 60. Borghaei H, Paz-Ares L, Horn L i sur. Nivolumab versus docetaxel in 69. Temel JS, Greer JA, Muzikansky A i sur. Early palliative care for pa- Advanced Non-small cell non-small cell lung cancer. N Engl J Med patients with metastatic non-small cell lung cancer. N Engl J Med 2010; 61. Brahmer J, Reckamp KL, Baas P i sur. Nivolumab versus docetaxel in 70. Vanste J, Crinò L, Do CMO i sur. 2nd ES consistent with advanced non-small cell non-small cell cancer.",
      "start_page": 1,
      "end_page": 7
    }
  ]
}